Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, and Cancer Immunotherapy and Biomarkers.
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Establishing Concordance of Next Generation Sequencing and Flow Cytometry Measures of B-Cell Recovery Post-CAR T Cell Therapy in B-ALL
Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Dynamics of B Cell Maturation Antigen (BCMA) Expression Pre-Treatment and at Relapse in Patients with Relapsed/Refractory Multiple Myeloma Receiving BCMA Directed CAR-T Cell Therapy
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion
Abstract 3940: Development of immunocomplex pediatric tumor organoids for onco-immunotherapy research
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia
Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Engineered CD47 protects T cells for enhanced antitumour immunity
PRC2-AgeIndex as a universal biomarker of aging and rejuvenation
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
Enhancing pediatric access to cell and gene therapies
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
323 Development of nuclear envelope protein-targeting CAR T cells for treatment of hyperproliferative<i>MYC</i>-driven group 3 medulloblastoma
Tumor inflammation-associated neurotoxicity
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL